To engage partners and stakeholders on awareness and education for infection associated chronic conditions (IACC).

To conduct performance evaluations, including operational characteristics of malaria rapid diagnostic tests submitted for WHO for assessment under the WHO Prequalification of In Vitro Diagnostics submitted to WHO for assessment under the Emergency Use Listing.

To support CDC with diagnostic development and processing for the global Guinea Worm Eradication Program (GWEP). This project will provide CDC with the laboratory support needed to diagnose possible Guinea worm (GW) specimens submitted by endemic and non-endemic countries and to validate and/or develop novel Guinea worm diagnostic tests.

To help implement the CDC Foundation programs and activities supporting the Targeted Country Assistance portion of the 2022-2025 Partners’ Engagement Framework.

To leverage the WHO Global Rotavirus Surveillance Network (GRSN) by using novel technology to achieve a better understanding of the role of enteric pathogens other than rotavirus in childhood diarrhea requiring hospitalization and create the Global Pediatric Diarrheal Surveillance Network (GPDS).

To support the introduction of a change in Burkina Faso’s infant pneumococcal vaccine schedule to include a booster dose and to evaluate the impact of the country’s capacity to control pneumococcal disease among children and adults.

To support the production and qualification of inactivated rotavirus vaccine clinical material.

To evaluate the impact of a pneumococcal conjugate vaccine schedule change in Mozambique on vaccine-type pneumococcal carriage and invasive pneumococcal disease; and serotype 1 colonization among patients with suspected pneumonia and serotype 1 disease among children and adults.

To support two annual two-day conferences for journalists from media outlets reaching rural, frontier and urban populations to provide training on where to access reliable health information.

To provide laboratory support for the analysis of immunogenicity and shedding of new oral Poliovirus vaccines in human clinical trials and related issues for polio endgame.

To evaluate the efficacy of injectable pre-exposure prophylaxis (PrEP) in HIV-uninfected populations.

To investigate other novel interventions, such as monoclonal antibodies (MAbs) against malaria. An intervention that could prevent malaria in children for a full 12 months in settings of perennial malaria transmission, such as Kenya, holds potential to reduce malaria morbidity and mortality substantially in this population at risk for severe malaria and death.

To support the chemistry, manufacturing and control (CMC) and preclinical development of an inactivated rotavirus vaccine.